This all-in-one strategy is particularly relevant for metastatic colorectal cancer cases whose MSI status contributes to tumour prognosis and patient selection for immunotherapy while KRAS, NRAS and BRAF genotyping helps for targeted therapies decision. The gene discussed is BRAF; the disease is metastatic colorectal cancer.